• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Semaglutide reduces cardiovascular risk in diabetics: The SUSTAIN-6 trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
November 11, 2016
in Cardiology, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The two-year risk of developing cardiovascular death, nonfatal myocardial infarction (MI) or stroke was approximately 25% less in patients taking semaglutide compared to placebo.

2. Two-year use of semaglutide linked to significantly lower levels for glycated hemoglobin (HbA1c) levels, weight and systolic blood pressure compared to placebo.  

Evidence Rating Level: 1 (Excellent)
­

Study Rundown: Semaglutide is an extended half-life glucagon-like peptitde 1 analogue that has not yet been approved for treatment of type 2 diabetes (T2DM). Its long-term cardiovascular side effects remain unknown. In this randomized, double-blind, placebo controlled trial, researchers attempt to understand if semaglutide treatment in patients greater than 50 years of age with established cardiovascular disease was noninferior to placebo with regards to cardiovascular death, nonfatal MI and/or stroke.

The result indicated that over the course of two years, participants on semaglutide were 25% less likely to experience the primary outcome composite of cardiovascular death, nonfatal MI or stroke. The decrease in risk was driven primarily by a significant decrease in the two-year risk of nonfatal stroke and a nonsignificant decrease in the two-year risk of nonfatal MI. However, there were no significant differences between groups for cardiovascular death, possibly due to the two year timeframe of the study. Additional significant differences in the semaglutide group included sustained decreases in HbA1c levels, weight loss and reduction in systolic blood pressures over the two-year study period. Overall, data from the study demonstrated not only noninferiority of semaglutide compared to placebo, but also significant clinical benefits compared to placebo.

Click to read the study, published today in NEJM

RELATED REPORTS

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes

Relevant Reading: Impact of Diabetes on Cardiovascular Disease: An Update

In-Depth [randomized controlled trial]: Researchers randomized 3297 patients to receive either semaglutide (n = 1648) or placebo (n = 1649), once-weekly at a doses of 0.5 mg or 1.0 mg. At baseline, 2735 (83%) of participants had established cardiovascular disease. The primary composite outcome was the first occurrence of cardiovascular death, nonfatal MI or stroke. The primary outcome occurred in 6.6% of the semaglutide group and 8.9% in the placebo group (HR 0.74; 95%CI 0.58-0.95; p < 0.001). Differences in nonfatal MI between semaglutide (47 patients, or 2.9%) and placebo (44 patients, 2.7%) groups were nonsignificant (HR 0.74; 95%CI 0.51-1.08; p = 0.12). However, nonfatal stroke occurred at a significantly lower rate in the semaglutide (27 patients, 1.6%) compared to the placebo (44 patients, 2.7%) group (HR 0.61; 95%CI 0.38-0.99; p = 0.04). In terms of adverse effects, rates of new or worsening nephropathy were lower in the semaglutide group (HR 0.64; 95%CI 0.46-0.88; p = 0.005), while rates of retinopathic complications were significantly higher in the semaglutide group (HR 1.76; 95%CI 1.11-2.78; p = 0.02). The mean glycated hemoglobin level at the study end-point was also significantly lower in the semaglutide compared to placebo group. The NNT to prevent one event of the primary outcome over 2 years was 45 patients.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular riskdiabetes mellitus
Previous Post

Dose-dense adjuvant chemotherapy not better than standard therapy for high-risk early breast cancer

Next Post

Ipilimumab prolongs survival in stage III melanoma: The EORTC 18071 trial

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Increased number of daily steps linked with decreased mortality in older women
Chronic Disease

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

May 29, 2025
Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes
StudyGraphics

Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes

March 13, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

February 28, 2025
Next Post
Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Ipilimumab prolongs survival in stage III melanoma: The EORTC 18071 trial

No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer

Nivolumab improves survival in head and neck squamous cell carcinoma: The CheckMate 141 trial

Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Pembrolizumab associated improved survival for NSCLC compared to platinum-based chemotherapy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.